|
|
Volumn 25, Issue 2, 2015, Pages 178-179
|
|
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma
|
|
Author keywords
Immune related adverse effect; Immunotherapy; Melanoma
|
|
Indexed keywords
IPILIMUMAB;
METHYLPREDNISOLONE;
NIVOLUMAB;
PEMBROLIZUMAB;
PREDNISONE;
ANTINEOPLASTIC AGENT;
CTLA4 PROTEIN, HUMAN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
MONOCLONAL ANTIBODY;
PDCD1 PROTEIN, HUMAN;
PROGRAMMED DEATH 1 RECEPTOR;
STEROID;
ARTHRITIS;
ARTICLE;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CASE REPORT;
COLITIS;
CORTICOSTEROID THERAPY;
DISEASE SEVERITY;
DRUG MONITORING;
DRUG SUBSTITUTION;
HUMAN;
HYPERTRANSAMINASEMIA;
HYPOPHYSITIS;
IRIDOCYCLITIS;
METASTATIC MELANOMA;
PRIORITY JOURNAL;
RHEUMATIC POLYMYALGIA;
THYROIDITIS;
VITILIGO;
ADVERSE EFFECTS;
ANTAGONISTS AND INHIBITORS;
CHEMICALLY INDUCED;
IMMUNE SYSTEM DISEASES;
IMMUNOLOGY;
IMMUNOTHERAPY;
MELANOMA;
SKIN NEOPLASMS;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CTLA-4 ANTIGEN;
HUMANS;
IMMUNE SYSTEM DISEASES;
IMMUNOTHERAPY;
MELANOMA;
PROGRAMMED CELL DEATH 1 RECEPTOR;
SKIN NEOPLASMS;
STEROIDS;
TREATMENT OUTCOME;
|
|
EID: 84924960204
PISSN: 09608931
EISSN: 14735636
Source Type: Journal
DOI: 10.1097/CMR.0000000000000132 Document Type: Article |
|
Times cited : (12)
|
|
References (6)
|
